NCT05875649尚未招募不适用
A Multicenter Prospective Cohort Study Study of CLAG Regimen in Acute Myeloid Leukemia Patients With First-induction Failure
适应症
试验速览
- 阶段
- 不适用
- 状态
- 尚未招募
- 入组人数
- 137
- 试验地点
- 1
- 主要终点
- Study of CLAG Regimen in Acute Myeloid Leukemia Patients With First-induction failure
研究概览
简要总结
Most of patients with acute myeloid leukemia achieved complete remission (CR) after primary induction chemotherapy, there were 20-30% patients without CR after first-induction. It was uncertain how to treat these patients. It was investigated in our study that these patients were re-induced with CLAG Regimen. The CR ratio, overall survival (OS) and relapsed-free survival (RFS) was statistically analysed in these patients.
研究设计
- 研究类型
- Observational
- 观察模型
- Case Only
- 时间视角
- Prospective
入排标准
- 年龄范围
- 14 Years 至 65 Years(Child, Adult, Older Adult)
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Acute myeloid leukemia patients with first-induction failure
排除标准
- •Acute myeloid leukemia patients with serious infection and organ dysfunction.
结局指标
主要结局
Study of CLAG Regimen in Acute Myeloid Leukemia Patients With First-induction failure
时间窗: 6 months
CLAG Regimen improves CR rate in acute myeloid leukemia patients with first-induction failure
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
终止
3 期
Leukemia Stem Cell Detection in Acute Myeloid LeukemiaAcute Myeloid Leukemia (AML)NCT02927938Wake Forest University Health Sciences18
已完成
2 期
Multi-center Study of Myeloablative Allo Stem Cell Transplant for Non-remission AML Using CloBu4 RegimenAcute Myeloblastic LeukemiaNCT01457885University of Michigan Rogel Cancer Center75
已完成
4 期
A Study for Improving the Outcome of Childhood Acute Promyeloid LeukemiaChildhood Acute Promyelocytic LeukemiaNCT02200978South China Children's Leukemia Group176
已完成
不适用
A Study of the Effectiveness of Venetoclax Tablets in Adult Acute Myeloid Leukemia Participants Ineligible for Standard Induction Therapy in Russian FederationAcute Myeloid Leukemia (AML)NCT04253314AbbVie51
已完成
2 期
Bendamustine, Lenalidomide (Revlimid®) and Dexamethasone (BRd) as 2nd-line Therapy for Patients With Relapsed or Refractory Multiple MyelomaMultiple MyelomaNCT01701076Cantonal Hospital of St. Gallen50
